Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Liabilities and Shareholders Equity (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $43.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 44.5% to $43.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $218.9 million, a 52.14% decrease, with the full-year FY2024 number at $66.3 million, down 53.47% from a year prior.
  • Liabilities and Shareholders Equity was $43.7 million for Q3 2025 at Lyra Therapeutics, down from $52.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $142.6 million in Q4 2023 to a low of $43.7 million in Q3 2025.
  • A 5-year average of $89.2 million and a median of $78.8 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 100.43% in 2022, then plummeted 60.21% in 2025.
  • Lyra Therapeutics' Liabilities and Shareholders Equity stood at $54.9 million in 2021, then surged by 100.43% to $110.0 million in 2022, then rose by 29.67% to $142.6 million in 2023, then tumbled by 53.47% to $66.3 million in 2024, then crashed by 34.12% to $43.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Liabilities and Shareholders Equity are $43.7 million (Q3 2025), $52.6 million (Q2 2025), and $56.3 million (Q1 2025).